What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 10.72% to $59.79. Ionis is a leader in antisense technology, with a strong pipeline and recent revenue growth, but faces challenges with high debt and low ROE.
August 26, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals has received a mix of bullish and bearish analyst ratings, with a recent increase in the average 12-month price target to $59.79. The company shows strong revenue growth but faces challenges with high debt and low ROE.
The majority of analysts have a bullish outlook on Ionis Pharmaceuticals, with an increase in the average price target indicating positive sentiment. The company's strong revenue growth supports this view, although high debt and low ROE present challenges. Overall, the positive analyst sentiment and price target increase suggest a likely short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100